Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

BF-200 ALA nanoemulsion formulation effective in photodynamic therapy for AK lesions

Oct. 21, 2009

Double-blind trial shows potential of mycophenolate mofetil in pemphigus vulgaris

Oct. 16, 2009

Provectus completes patient accrual and initial treatment in phase II trial of PH-10

Oct. 14, 2009

Cellceutix reports results of KM-133 study in human xenograft mouse model of psoriasis

Oct. 9, 2009

Cipher begins enrollment in phase III CIP-Isotretinoin trial in severe nodular acne

Oct. 9, 2009

R-Tech Ueno begins early phase II trial of RK-023 for male pattern baldness

Oct. 7, 2009

Can-Fite BioPharma initiates preparation for phase III psoriasis trial of CF-101

Oct. 6, 2009

Welichem Biotech files CTA for phase II trial of WBI-1001 in atopic dermatitis

Oct. 5, 2009

Centocor's Stelara approved by the FDA for moderate to severe plaque psoriasis

Sep. 29, 2009

Janssen-Cilag's Stelara approved in UK for plaque psoriasis

Sep. 25, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 1, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...